Drug Trial Radar · NCT04740931
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
Last checked: Nov 20, 2026Latest source record: Aug 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
729
Actual
Start
Mar 2, 2021
Primary completion
Aug 9, 2022
Study completion Jul 12, 2023
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Feb 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in patients with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).
Conditions
- Macular Edema
- Central Retinal Vein Occlusion
- Hemiretinal Vein Occlusion
Interventions
FaricimabDrug
Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
AfliberceptDrug
Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
Sham ProcedureProcedure
The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24Time frame: From Baseline through Week 24
Locations
194 sites in 22 countries. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center
Mesa, Arizona
Retinal Research Institute, LLC
Phoenix, Arizona
Retina Associates Southwest PC
Tucson, Arizona
Retinal Diagnostic Center
Campbell, California
The Retina Partners
Encino, California
Retina Consultants of Orange County
Fullerton, California
Northern California Retina Vitreous Associates
Mountain View, California
East Bay Retina Consultants
Oakland, California
California Eye Specialists Medical group Inc.
Pasadena, California
Retina Consultants, San Diego
Poway, California
West Coast Retina Medical Group
San Francisco, California
Retina Consultants of Southern Colorado PC
Colorado Springs, Colorado
Colorado Retina Associates, PC
Lakewood, Colorado
Retina Group of New England
Waterford, Connecticut
Advanced Research
Deerfield Beach, Florida
Rand Eye
Deerfield Beach, Florida
Florida Eye Associates
Melbourne, Florida
Fort Lauderdale Eye Institute
Plantation, Florida
Retina Vitreous Assoc of FL
St. Petersburg, Florida
Retina Associates of Florida, LLC
Tampa, Florida
Southeast Retina Center
Augusta, Georgia
Georgia Retina PC
Marietta, Georgia
Retina Consultants of Hawaii
‘Aiea, Hawaii
Northwestern Medical Group/Northwestern University
Chicago, Illinois
Retina Associated Ltd
Elmhurst, Illinois
University Retina and Macula Associates, PC
Oak Forest, Illinois
Prairie Retina Center
Springfield, Illinois
Retina Associates
Lenexa, Kansas
Johns Hopkins Med; Wilmer Eye Inst
Baltimore, Maryland
Retina Group of Washington
Chevy Chase, Maryland
Cumberland Valley Retina PC
Hagerstown, Maryland
Assoc Retinal Consultants PC
Royal Oak, Michigan
VitreoRetinal Surgery, PLLC.; DBA Retina Consultants of Minnesota
Edina, Minnesota
Midwest Vision Research Foundation
Chesterfield, Missouri
Sierra Eye Associates
Reno, Nevada
Long Is. Vitreoretinal Consult
Hauppauge, New York
Retina Vit Surgeons/Central NY
Liverpool, New York
Retina Assoc of Western NY
Rochester, New York
Cincinnati Eye Institute
Cincinnati, Ohio
Retina Northwest
Portland, Oregon
Showing 40 of 194 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.